Treatment of Tuberculosis | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Tuberculosis (TB) remains a leading cause of death globally. Dissemination of TB to the
brain results in the most severe form of extrapulmonary TB, tuberculous meningitis (TBM) …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Background Tuberculous meningitis is often lethal. Early antituberculosis treatment and
adjunctive treatment with glucocorticoids improve survival, but nearly one third of patients …

Drug-resistance testing, or antimicrobial susceptibility testing (AST), is mandatory for
Mycobacterium tuberculosis in cases of failure on standard therapy. We reviewed the …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

WHO estimates that 9 million people developed active tuberculosis in 2013 and 1· 5 million
people died from it. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development
to characterize pharmacokinetics (PK) and pharmacodynamics (PD). Pharmacokinetic …

Tuberculosis (TB) is the leading cause of death from a single infectious agent, requiring at
least 6 months of multidrug treatment to achieve cure. However, the lack of reliable data on …